Tag Archive for: The Michael J. Fox Foundation

Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease

Copenhagen, Denmark, 23rd January 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the Company has been awarded a grant (MJFF-024128) worth c.US$873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease. The […]

Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies

Lausanne, SWITZERLAND and San Francisco, CA, USA, 4 May 2022 – Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today announces that it has been awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the study of its clinical stage O-GlcNAcase (OGA) […]